-
[show abstract]
[hide abstract]
ABSTRACT: Various treatments for oropharynx cancer included radiotherapy, arterial injection chemotherapy (as well as combined chemoradiotherapy), combined concurrent chemoradiotherapy, and surgical resection and reconstruction. There are also treatment differences among facilities. Our department has been providing a treatment modality for head and neck malignancies with the aims of functional and morphological preservation with a high cure rate. We herein report the treatment efficacy in 7 cases of oropharynx cancer (6 cases on lateral wall and 1 case on superior wall)treated with S-1, nedaplatin and radiotherapy (SN therapy) at our department between April 2006 and December 2006. The total of 7 cases included 1 case of T1N1M0, 1 of T2N0M0, 2 of T2N2bM0, 1 of T2N2cM0, 1 of T3N2cM0, and 1 case of T4N2cM0. The patients were all male and their ages ranged from 57 to 76 years old, with the average age of 68.4 years. Six of the 7 cases are surviving without cancer through treatment and their functions and morphologies have been preserved. In the 1 case of T4N2cM0, the tumor did not disappear and the patient expired due to the original lesion. Although SN therapy supposedly enables functional and morphological preservation, it is necessary to increase the number of cases and examine the efficacy of SN therapy for oropharynx cancer for functional and morphological preservation and the survival rate.
Gan to kagaku ryoho. Cancer & chemotherapy 08/2010; 37(8):1535-7.
-
[show abstract]
[hide abstract]
ABSTRACT: There are a variety of reports on radiotherapy, combined chemotherapy with radiation (including arterial injection), block resection via surgery, and fractional resection for maxillary cancer, and currently various differences among facilities. In our department, we provide treatment with the aim of preserving the organs and functions in cases of head and neck malignant tumors. We herein report the effectiveness of treatment in 4 cases of maxillary cancer, using S-1, nedaplatin/radiation (SN) therapy at our department from January 2005 to December 2008. The cases comprised 4 patients, including 3 cases of T4N0M0 and 1 case of T2N0M0. All patients were males between 29 to 67 years old, wherein the mean was 52.3 years old. All cases resulted in survival without cancer after the application of the treatment policy of our department, wherein all functions were preserved. It is believed that the performance of SN therapy made it possible to minimize the scope of surgery and preserve the organs and functions. It will be necessary to increase the number of cases in order to examine the effectiveness of the organ and function preservation as well as the survival rate for maxillary cancer after SN therapy.
Gan to kagaku ryoho. Cancer & chemotherapy 05/2010; 37(5):879-82.
-
[show abstract]
[hide abstract]
ABSTRACT: Laryngeal cancer occurs more frequently in head and neck cancers, so there are a number of reports regarding the treatment results,wherein the therapeutic strategy and results are stable to some extent. However, due to the spread of chemoradiotherapy, there are differences in the larynx preservation rates for T2 and T3 cases, depending on the facility. Our department has been administering chemoradiotherapy for advanced cancer based on the perspective of conserving the organ and the function. We herein report our examination of 20 laryngeal cancer cases receiving concomitant therapy with S-1, Nedaplatin, and radiation (hereinafter, referred to as SN therapy) in our department from April 2005 to December 2008. The resulting complete response (CR) rate for the SN therapy was 82.4%, excluding T4 cases. Due to their refusal of surgery, 2 of 3 cases in which the SN therapy had been administered for T4 cases receiving SN therapy showed CR, wherein the CR rate in all cases after the SN therapy was 80. 0%. The larynx preservation rate after the SN therapy was 94.1%.
Gan to kagaku ryoho. Cancer & chemotherapy 02/2010; 37(2):241-4.
-
[show abstract]
[hide abstract]
ABSTRACT: The development of reconstructive surgery and the use of free flaps have allowed for a larger dissection range even for advanced tongue cancer, resulting in an improvement of the prognosis. However, both the postoperative swallowing and masticatory function are still considered to have not yet reached a satisfactory level. Accordingly, our department has been administering concurrent chemoradiotherapy (CCRT) for advanced cancer to preserve the organ and the function; there are cases in which even comparatively small tumors are difficult to dissect due to the occurrence site. We have been treating these cases using CCRT as well. We herein report our results of 10 tongue cancer cases in which CCRT with S-1 and Nedaplatin (hereinafter, referred to as SN therapy) was administered in our department from April 2002 to October 2008. The complete response rate of the SN therapy was 60. 0% (6 of 10 examples). The 5-year disease-specific survival rates were 50. 0% for Stage II, 75. 0% for Stage III, and 75. 0% for Stage IV, respectively.
Gan to kagaku ryoho. Cancer & chemotherapy 12/2009; 36(13):2561-4.
